Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | LIG1 | P18858 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1340388 | 0.90 | HSD17B2 (0.52) | KDM4ETSHRGAACYP3A4KMT2A | |
| SCHEMBL2523828 | 0.87 | KDM4E (0.49) | KDM4ETSHRGAASNCACYP3A4 | |
| SCHEMBL13690626 | 0.86 | KDM4E (0.57) | KDM4ETSHRGAASNCACYP3A4 | |
| SCHEMBL8786876 | 0.82 | TSHR (0.50) | KDM4ETSHRGAASNCACYP3A4 | |
| SCHEMBL2524549 | 0.82 | KDM4E (0.47) | KDM4ETSHRGAASNCACYP3A4 | |
| SCHEMBL19511252 | 0.82 | KDM4E (0.47) | KDM4ETSHRGAASNCACYP3A4 | |
| SCHEMBL680755 | 0.81 | KDM4E (0.71) | KDM4ETSHRCYP3A4KMT2AMEN1 | |
| SCHEMBL31737297 | 0.81 | KDM4E (0.71) | KDM4ETSHRCYP3A4KMT2AMEN1 | |
| SCHEMBL5102380 | 0.81 | KDM4E (0.54) | KDM4ETSHRSNCACYP3A4KMT2A | |
| SCHEMBL13690602 | 0.81 | KDM4E (0.48) | KDM4ETSHRGAASNCACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486992-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2013-07-16 | — | — | US | disclosed |
| US-8268881-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2012-09-18 | — | — | US | disclosed |
| CN-101268046-B | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER | 2012-07-25 | — | — | CN | disclosed |
| US-20110251164-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2011-10-13 | — | — | US | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-7772223-B2 | 5-Methyl-5-(3-phenoxyazetidin-1-yl)-2,2-diphenylhexanamide, used for the treatment of respiratory system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis and emphysema | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-02-04 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1928821-B1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| CN-101268046-A | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LTD (GB) | 2008-09-17 | — | — | CN | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1928821-A1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
| WO-2007034325-A1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2007-03-29 | — | — | WO | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | KDM4E 1843/4885TSHR 3211/4885GAA 92/4885 |
| US-20110251164-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | KDM4E 2040/4885TSHR 104/4885GAA 3248/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | KDM4E 1843/4885TSHR 3211/4885GAA 92/4885 |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | KDM4E 2040/4885TSHR 104/4885GAA 3248/4885 |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | KDM4E 2040/4885TSHR 104/4885GAA 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.